JMP Securities analyst Donald Ellis downgraded Revance Therapeutic (NASDAQ: RVNC) from Market Outperform to Market Perform.The analyst cites a challenging ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE